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Effect of fluoride on aluminum-induced bone disease in rats with renal
failure. Aluminum (Al) accumulation in renal failure is an etiological
factor in the pathogenesis of low turnover bone disease. Aluminum-
induced impairment of mineralization has been related to a reduced
extent of active bone-forming surface. The present study investigated
the effect of fluoride, a potent stimulator of osteoblast number, on the
toxicity of aluminum in rats with renal failure (Nx). Following a large
parenteral aluminum load (3.2 mg/kg x day) over a period of nine
weeks, bone histomorphometry of vertebral cancellous bone revealed a
severe low-turnover osteodystrophy as evidenced by a fall in osteoblas-
tic osteoid surfaces and mineral apposition rates. Concurrent adminis-
tration of fluoride [20 mg/liter (F20) or 40 mg/liter (F40) supplied with
the drinking waterl resulted in a significant increase in the number of
osteoblasts (Nx + Al + F40 vs. Nx + Al, 33.75 2.83 vs. 1.81 0.43
mm, P C 0.001) together with an overall reduced deposition of
aluminum in bone (469.3 24.6 vs. 592.2 28.3 pg/g, P C 0.01).
However, there was an increase in the fraction of osteoid surface
exhibiting stainable aluminum at the bone-osteoid interface (70.7 7.1
vs. 44.3 6.0%, P < 0.005). Fluoride-exposed rats accumulated a
significantly larger osteoid volume, suggesting an exacerbation of the
ostcomalacic lesion, and furthermore, dynamic histomorphometric
parameters remained depressed. These results indicate that fluoride has
a distinct effect on the pattern of aluminum deposition in bone. In
addition, fluoride antagonizes the aluminum-induced reduction in os-
teoblast uumber but provides no amelioration of the impaired mineral-
ization in aluminum-intoxicated rats. Thus, in this model a decrease in
the extent of osteoblast surface does not account for the development of
aluminum-related bone disease. Aluminum toxicity in the presence of
fluoride may involve physical-chemical inhibition of mineralization or
altered cellular activity of osteoblasts.
Tissue accumulation of aluminum in chronic renal failure is
associated with the occurrence of several clinical disorders
including dialysis dementia, aluminum-related bone disease and
hypochromic, microcytic anemia [1—4]. Considerable circum-
stantial evidence suggests that aluminum is an etiological factor
in the evolution of adynamic bone disease and osteomalacia in
dialysis patients, however, the precise pathogenesis of the
aluminum-induced bone lesion is still controversial. In vitro,
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aluminum has been demonstrated to adsorb on calcium hy-
droxyapatite crystals and to severely inhibit their growth or
dissolution [5]. In vivo, aluminum is localized at the interface of
mineralized bone and unmineralized osteoid [6, 7]. Both find-
ings are consistent with the view that the deposition of alumi-
num at the mineralization front may directly inhibit osteoid
calcification by physical-chemical effects. However, recent
studies indicate that apart from direct inhibition of mineraliza-
tion additional mechanisms mediate the toxicity of aluminum.
Histomorphometric evaluation of experimental and human alu-
minum-related bone disease consistently revealed a reduction
in the number of bone forming cells, and it has been postulated
that a progressive decline in the extent of osteoblastic osteoid
surface together with a disturbance in the functions of osteo-
blasts may be the primary event in the sequence leading to
low-turnover bone disease [8—10]. Since parathyroid hormone is
a major determinant of osteoblast number in bone [11], these
adverse effects of aluminum have been explained on the basis of
an aluminum-induced suppression of parathyroid hormone se-
cretion [12]. In addition, a direct toxic effect of aluminum on
bone cells has been suggested [13]. Recently, evidence has been
provided that, at least in an experimental model of aluminum-
related osteomalacia, bone formation at the cellular level may
be normal and that the low remodeling activity of aluminum-
loaded bone may predominantly result from a decrease in the
number of metabolically active osteoblasts [14].
In part these conflicting results could be attributable to the
fact that the histological response of bone to aluminum may be
significantly altered by the hormonal status, the uremic milieu
and the presence of other bone-seeking elements. With respect
to the latter factor the present study investigated whether
fluoride, a potent stimulator of osteoblast number, would mod-
ify the detrimental effect of aluminum on bone forming cells in
an uremic rat model, and if so, whether the interaction of
aluminum and fluoride would yield implications for the patho-
genesis of aluminum-related bone disease. In addition, we
sought to determine whether fluoride would affect the deposi-
tion of aluminum in bone. The results indicate that fluoride has
an influence on both accretion rate and distribution of aluminum
in cancellous bone and that fluoride changes the histological
appearance of the aluminum-induced bone lesion in the rat.
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Table 1. Effect of fluoride and aluminum on uremic bone disease in
subtotally nephrectomized rats: Experimental protocol
Group N Days 1—14 Days 15—77
Nx 10 — Na lactate
Nx + Al 10 — Al(Iactate)3
Nx + F20 9 F20 F20 + Na lactate
Nx + F40 10 F40 F40 + Na lactate
Nx + Al + F20 9 F20 F20 + Al(lactate)3
Nx + Al + F40 8 F40 F40 + Al(lactate)3
Abbreviations are: Nx, 5/6 nephrectomy; N, number of surviving
animals. Aluminum (Al) i.p.; Al(lactate)3 3.2 mg/kg per day; Na lactate
i.p., 13.3 mg/kg per day; fluoride (F 20); NaF p.o., 20 mg/liter; fluoride
(F 40); NaF p.o., 40 mg/liter.
Methods
Experimental protocol
Male Sprague-Dawley rats (Han: SPRD, Dept. of Lab. Ani-
mal Res., RWTH) weighing 180 to 220 g, six weeks of age, were
rendered uremic by a two-stage 5/6 nephrectomy (Nx) [15]. A
left two-third nephrectomy was followed one week later by a
total right nephrectomy, and care was taken in both instances to
avoid damage to the adrenal gland. Two weeks after the second
operation rats matched for weight and residual renal function
were allocated to six groups of 10 rats each (Table I). After
assignment to their respective groups rats received either 20
mg/liter or 40 mg/liter fluoride supplied with deionized drinking
water as sodium fluoride [equivalent to 44.2 mg/liter (1.05 mM)
and 88.4 mg/liter (2.11 mM) NaF, respectively]. Fourteen days
after the onset of fluoride treatment aluminum-exposed rats (Nx
+ Al + F20 and Nx + Al + F40) received 3.2 mg/kg aluminum,
i.p. administered as aluminum lactate dissolved in deionized
water to yield a final aluminum concentration of 2 mg/mI.
Injections were administered daily for nine weeks. It was
decided to start fluoride exposure prior to administration of
aluminum to allow some fluoride effects on bone to develop
before aluminum-induced suppression of osteoblast number
and activity would occur. To evaluate the effect of fluoride per
se in chronic renal failure, additional rats received graded
concentrations of fluoride with their drinking water for II
weeks (Nx + F20 and Nx + F40) without concomitant alumi-
num injections. An additional Nx group was loaded with
aluminum for nine weeks but received deionized drinking water
instead of fluoride (Nx + Al), and a final group served as uremic
controls (Nx). Intraperitoneal injections of sodium lactate were
given to rats not treated with aluminum. All animals had free
access to water, but were pair-fed with a low fluoride diet (C
1044, Altromin, Lage, Germany) containing 0.6 mg/kg fluoride
together with adequate concentrations of calcium (0.95%) and
phosphorus (0.75%). A total of four animals died before the
study was completed (Table 1).
Fourteen days prior to sacrifice all animals were injected with
2 mg rolitetracycline (Hoechst, Frankfurt, Germany) at 12 hour
intervals during three days, followed by a labeling free interval
of eight days. For the second label 2 mg demeclocycline
(Lederle, Wolfratshausen, Germany) was injected six times at
12 hour intervals. Twenty-four hours after the last injection
animals were anesthetized with ether, exsanguinated by abdom-
inal aortic puncture and tibia, the fourth lumbar vertebra,
spleen and liver were removed.
Analytical procedures
Serum analysis of calcium was performed by atomic absorp-
tion (Perkin-Elmer 2380, Norwalk, Connecticut, USA), serum
phosphate was measured by a colorimetric method (Boehringer
Mannheim, Germany), and serum creatinine was determined by
an autoanalyzer (Beckman Creatinine Analyzer II, Fullerton,
California, USA). Activity of serum alkaline phosphatase was
measured by a colorimetric method (Boehringer). Serum immu-
noreactive parathyroid hormone (PTH) was determined by a
radioimmunoassay recognizing the mid-molecule sequence (44-
68) of PTH employing a reference standard from rat parathyroid
homogenates (Immuno Nuclear Corporation, Stillwater, Min-
nesota, USA). Serum and urine aluminum was measured by
flameless atomic absorption using a 2380 spectrophotometer
equipped with a HGA-400 flameless furnace employing a non-
pyrolyzed graphite tube and an AS-40 automatic sample injec-
tor (20 l sample size; Perkin-Elmer) as previously described
[16]. Aluminum as well as fluoride were measured in tibial
cancellous bone since at this skeletal site we were able to obtain
specimen of cancellous bone devoid of cortical bone. For
aluminum determination in bone, tibiae were bisected and
marrow was removed with a jet of deionized water. Dried
samples of cancellous bone were ground to powder in an agate
mill, defatted (petroleum ether/ether, 1:1 vol:vol), digested with
nitric acid (Suprapur, Merck, Darmstadt, Germany; Al content
< 4 igIliter), diluted with distilled water and analyzed as
reported earlier [17]. Aluminum concentrations in spleen and
liver were analyzed following EDTA extraction [18]. The
results are expressed in g Al/g dry weight. In aluminum-
treated animals determination of fluoride concentrations in
bone in the presence of either TISAB II, TISAB III or TISAB
IV yielded results of poor reproducibility and recovery. Thus,
fluoride concentrations in cancellous bone were analyzed in
presence of an acetate-citrate buffer [19]. Dried samples of
cancellous bone were ashed at 550°C for 16 hours in platinum
crucibles, and 50 mg bone ash was dissolved in 1 ml of 4 M
HNO3, Ten ml of aS M acetate-0.5 M citrate buffer (pH 5.0) and
2 ml 3 M NaOH were added and the solution diluted to 25 ml.
Aliquots were analyzed for fluoride by means of an ion selective
electrode (Orion Model 96-09-00 equipped with an Expandable
Ion Analyzer EA 940, Cambridge, Massachusetts, USA) at
21°C. Calibration was performed using standard solutions (Ori-
on) prepared with the same amounts of HNO3, NaOH, and
acetate-citrate buffer, and readings on a logarithmic scale were
linear between 1 mg/liter and 100 mg/liter fluoride. By use of the
acetate-citrate buffer replicate determinations of bone material
containing 0.92 mg/g and 8.09 mg/g fluoride (ash weight) yielded
a coefficient of variation of 1.9% and 2.3%, respectively.
Average fluoride recoveries were 98.9% and 97.1% in bone of
Nx rats and in bone of aluminum-treated rats, respectively.
Bone histomorphometry
Vertebral cancellous bone was used for histomorphometry,
since at this skeletal site sequential bone remodeling has been
demonstrated in the rat [20]. The fourth lumbar vertebra was
longitudinally divided in the central area and fixed in 40%
ethanol at 4°C for one day, transferred to 70% ethanol, dehy-
drated and embedded in methyl methacrylate. Serial sections of
5 m and 10 m thickness were cut using a Jung microtome
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Table 2. Body weight and plasma chemistry in 6 groups of uremic rats treated with a!uminum (Al) and graded doses of fluoride (F)
Mx Nx+A1 Nxl-F20 Nx+F40 Mx+Al+20 Nx±A1±F40 P
Body weightg 340±17 313 17 333 12 338 13 328 18 322±15 NS
Creatinine (day 0) 1.1 0.1 1.0 0.1 1.0 0.1 1.1 0.2 1.0 0.1 1,0 0.1 NS
,ng/dl
Creatinine (day 77) 1.0 or 3.7 04b 1.1 o.2 1.1 0.2a 3.0 04b 14b co.ooi
mg/dl
Calcium mg/dl 11.7 0.3 10.2 0.4 10.7 0.3 10.5 0.2 10.2 0.4 10.2 0.2 NS
Phosphate mg/dl 9.9 0.2 13.3 1.4 9.4 0.8 8.9 0.7 12.8 1.6 12.9 1.7 NS
Alkaline phosphatase 157 42 218 48 170 24 120 15 142 13 233 52 MS
U/liter
PTH(dayo) 131±11 127±10 114±11 115±12 122±19 122±18 NS
pmol/liter
PTH (day 35) 143 11a,b 176 26a,b 111 8a 164 39a.b 179 37a,b 228 39b <0.05
pmol/liter
PTH (day 77) 229 54 464 8O 222 40 218 32 398 80al 516 62b co.oos
pmol/liter
Blood samples were obtained at the end of the experimental protocol (day 77), except where noted otherwise. Values with the same superscript
are not statistically different; P denotes the result of the Kruskal-Wallis test (NS: not significant)
(Modell K, Heidelberg, Germany). For histomorphometric
analysis 5 1am Goldner stained sections were examined, the
presence of stainable aluminum was quantified in 5 pm sections
employing the aurine tricarboxylic stain [21]. Ten-jim thick
sections were prepared for fluorescent light microscopy and
utilized for examination of tetracycline labels. Histomorpho-
metric analysis of the cancellous bone in each section was
accomplished by evaluating a minimum of 60 fields at a magni-
fication of x 250 on at least three non-consecutive sections with
the aid of a Leitz microscope (Wetzlar, Germany), using a
digitizer interfaced with a computer. The histomorphometry
nomenclature of the American Society of Bone and Mineral
Research was used [22]. The following histomorphometric
parameters were evaluated: (a) bone volume (BY/TV), the
fraction of tissue volume (TV) occupied by osteoid and miner-
alized bone; (b) osteoid volume (OV/BV), the percentage of
cancellous bone volume composed of osteoid; (c) osteoid
surface (OS/BS), fraction of cancellous bone surface covered
by osteoid; (d) mean osteoid thickness (O.th), measured di-
rectly; (e) osteoblast surface (Ob.S/BS), fraction of cancellous
bone surface on which osteoblast-covered osteoid is present; (t)
osteoblastic osteoid surface (Ob.S/OS), fraction of osteoid
surface covered by cuboidal osteoblasts; (g) number of osteo-
blasts per mm osteoid perimeter length (N.Ob/O.Pm); (h)
osteoclast surface (Oc.S/BS), fraction of cancellous bone sur-
face covered with osteoclasts; (i) stainable bone aluminum at
the bone-osteoid interface (Al.S/OS); (j) stainable bone alumi-
num at the mineralized surface (Al.S/Md.S); (k) mineral appo-
sition rate (MAR), determined by dividing the average distance
between the two tetracycline labels (jim) by the time interval (d)
between the middle of the first and the middle of the second
label; (1) mineralizing osteoid surface (MS/OS), fraction of
osteoid surface exhibiting two tetracycline labels plus half the
fraction of the single-labeled osteoid surface; (m) mineralizing
bone surface (MS/BS), fraction of bone surface exhibiting two
tetracycline labels plus half the fraction of the single-labeled
bone surface; (n) adjusted apposition rate (Aj.AR), calculated
by multiplying MAR by MS/OS; (o) mineralized bone formation
rate (Md.BFR/BS), obtained by multiplying MAR by MS/BS;
(p) osteoid maturation time (Omt), obtained by dividing O.th by
MAR; (q) mineralization lag time (Mlt), obtained by dividing
O.th by Aj.AR. Osteoid thickness and the distance between
tetracycline labels were corrected for obliquity with the factor
rn'4.
All reported data are expressed as mean value 1 standard
error of the mean. Statistical probabilities are derived from the
Kruskal-Wallis test, a non-parametric analysis of variance,
followed by a sequentially rejective multiple test procedure to
compare specific groups [23]. A value of P c 0.05 was consid-
ered significant. Correlation between two parameters was ac-
complished by Spearman rank correlation.
Results
At the end of the experimental period, 77 days after assign-
ment of uremic rats to their respective treatment, no significant
differences in body weights could be demonstrated between the
pair-fed study groups (Table 2). Residual renal function had
deteriorated in Al groups as reflected by higher serum creati-
nine concentrations. In addition, aluminum-loaded rats tended
to have increased serum phosphate concentrations. Serum
calcium was similar among the various treatment groups. Con-
comitant administration of fluoride and aluminum tended to
increase serum alkaline phosphatase in group Nx + Al + F40,
whereas slightly reduced activities of alkaline phosphatase were
observed with high dose fluoride in the absence of aluminum
exposure (Nx + F40). However, variance was large and the
overall differences did not achieve statistical significance. As
compared to uremic controls PTH serum concentrations were
significantly elevated in group Nx + Al + F40. Compared with
serum PTH on days zero and 35, marked progression of
secondary hyperparathyroidism occurred in all aluminum
groups concurrent with deterioration of renal function.
As expected, intraperitoneal injections of aluminum resulted
in grossly elevated serum aluminum concentrations and a large
increase in urinary aluminum excretion rates in the respective
treatment groups (Table 3). Administration of fluoride exerted
no discernible effects on serum aluminum or aluminum excre-
tion. There was, however, a significant correlation between the
magnitude of residual renal function as assessed by serum
creatinine and renal aluminum elimination when the pooled data
of all Al groups were analyzed (r = —0.47, P C 0.01). Bone
Ittel et a!: Effect of fluoride on Al-induced bone disease 1343
Table 3. Aluminum excretion rates and aluminum concentrations in serum, bone, liver, and spleen and fluoride concentrations in cancellous
bone of uremic rats after administration of aluminum (Al) and fluoride (F)
Nx Nx + Al Nx + F20 Nx + F40 Nx + Al + F20 Nx + Al + F40 P
Serum Al 4 l 1800 282" 6 ia 6 ia 2203 516" 1859 291b <0001
I.tg/liter
Urine Al 0.41 0,06k 168.23 35.83" 0.49 O.O9 0.63 0.l0 182.67 22.88" 162.40 3388b <0.001
pg/day
Bone Al 4.9 0.4a 592.2 28.3" 4.4 l.5a 5.4 l.6 462.9 28.5c 469.3 24.6c <0.001
,.Lg/g
Liver Al 0.8 0.5a 600.8 78.9" 1.5 0.7a 2.3 0.8k 547.3 56.6" 605.9 l06.6t <o.ooi
ji.g/g
Spleen Al 1.1 0.3a 1152.4 955b 1.9 0.6a 2.8 l.6a 1093.8 1450b 1350.9 2575b <0001
j.g/g
Bone F 1.19 0.02a 0.78 0.07a 4.35 1.05" 8.72 l.40c 577 090b 9.30 0.57c <0.001
mg/g
Values with the same superscript are not statistically different.
P denotes the result of the Kruskal-Wallis test
aluminum content was low in group Nx as compared to previ-
ously published data [17] and did not appear to be affected by
ingestion of fluoride (Nx + F20 and Nx + F40). As a result of
parenteral aluminum loading a significant increment in bone
aluminum concentration could be demonstrated in group Nx +
Al rats. However, analysis of bone aluminum by atomic absorp-
tion revealed clear-cut differences between the various Al
groups. Pretreatment and concurrent administration of fluoride
with either dose significantly reduced aluminum deposition in
bone as compared to group Nx + Al despite of comparable
doses of aluminum, which were injected within a period of 63
days (Nx + Al 55 2 mg Al; Nx + Al + F20 59 3 mg Al; Nx
+ Al + F40 57 2 mg Al). In contrast, treatment with fluoride
did not affect the degree of aluminum accumulation in spleen
and liver. Cancellous bone content of fluoride rose dose-
dependently in rats supplied with fluoride in their drinking
water, and at a given dose level this increment in bone fluoride
was larger in aluminum-treated groups with a more compro-
mised renal function. At the same dose level cumulative doses
of fluoride were similar among F-groups (Nx + F20 34 4mg;
Nx+Al+F2030±2mg;Nx+F4058±4mg;Nx+Al+
F40 61 2 mg).
Upon light microscopy histochemical staining for aluminum
demonstrated linear, red-stained deposits at the interface of
osteoid and mineralized cancellous bone as well as on mineral-
ized surfaces in all aluminum-treated groups (Fig. 1). Aluminum
stains were negative in rats not treated with aluminum. Stain-
able bone aluminum in aluminum-fluoride groups did not mirror
their lower bone aluminum content. The larger the fluoride dose
used, the more aluminum was demonstrable at the bone-osteoid
interface. This finding was contrasted by a significantly reduced
aluminum stain at mineralized surfaces in fluoride groups.
Measurement of static and dynamic histomorphometric pa-
rameters in vertebral cancellous bone revealed striking effects
of aluminum and fluoride (Tables 4 and 5). Sole administration
of aluminum produced an adynamic bone disease characterized
by a 12-fold and threefold increase in osteoid volume and
osteoid surface, respectively. In parallel, there was a fivefold
increase in osteoid thickness. Rarely were osteoid surfaces
covered by osteoblasts. In general, tetracycline labels were
absent in group Nx + Al and only few, less intense irregular
labels extending into the osteoid were observed. In the absence
of aluminum, fluoride increased osteoid surfaces. At the cellular
level, there was an increase in osteoblastic osteoid surfaces and
osteoblast number, however, fluoride failed to stimulate MAR
and Omt tended to rise in a dose-related fashion. Likewise,
Aj .AR tended to fall and Mlt was prolonged. At the tissue level
Md.BFR fell, though not significantly.
Concurrent exposure to aluminum and the larger dose of
fluoride (Nx + Al + F40) increased the extent of Ob.SIOS and
Ob.SIBS to a level greater than 6 times and 31 times that
observed in group Nx + Al, respectively (Table 4). This
increase exceeded the extent of osteoblastic osteoid surface and
osteoblast surface in groups Nx + F20 and Nx + F40. In
parallel, fluoride-treated, aluminum-loaded rats accumulated a
sevenfold larger amount of osteoid volume as compared to Nx
+ Al and exhibited an increase in osteoid surface of a corre-
sponding degree. As a consequence of the severe osteoidosis,
cancellous bone volume almost doubled in rats exposed to
fluoride and aluminum. Despite the increment in osteoid sur-
faces lined by osteoblasts MAR and Md.BFR remained de-
pressed. Similar changes, although less marked, were noted
when the lower dosage of fluoride was employed.
80
60
40
*
_ H.
Nx+AI Nx+AI+F20 Nx+AI+F40
Fig. 1. Stainable aluminum at the bone-osteoid interface (, %) and
stainable aluminum at the mineralized surface (D, %) in vertebral
cancellous bone in uremic rats loaded with aluminum (Nx + Al) and in
rats receiving aluminum together with fluoride at two dose levels (Nx +
Al + F) (* P < 0.05 vs. Nx + Al).
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Table 4. Static parameters of cancellous bone histomorphometry in 6 groups of uremic rats after administration of aluminum (Al)
and fluoride (F)
Nx Nx + Al Nx + F20 Nx + F40 Nx ÷ Al + F20 Nx + Al + F40 P
BV/TV % 19.6 0,7k 17.8 l.Oa 18.3 l.la 22.1 l.8" 32.2 28b 31.5 30b <0.001
OV/BV % 0.7 0.la 8.4 0.9" 2.9 l.l 4.1 07a.b 67.9 2.6c 60.6 44C <0.001
OSIBS% 5.3 1.Oa 13.6 13,b 14.7 3.6a 15.3 20b 75,2 5.5 60.6 44C <0.001
O.th pm
Ob.S/Bs %
4 ia
1.8 0.5
20 3
1.7 0.4
6 ia
8.7 22a,b
4fl
8.2 1.9
46 11b
39,7 12b,c 52.1 3.8c
<0.001
<0.001
Ob,S/OS % 30.3 37a 12.8 26b 61.3 6.6c( 48.0 7,3C 52.4 28,b 86.9 4,3d <0.001
N.ObIO.Pm mm' 4,44 090a.b 1.81 0,43" 16.18 4.15k 13.83 2.46a 16.15 1.36a 33.75 2.83c <0.001
Oc.S/BS % 3.2 0.8 0.3 01b 1.6 05a.b 3.4 o.6 4.0 Q5C 5.5 1.2c <0.001
Values with the same superscript are not statistically different. Abbreviations are in the text. P denotes the result of the Kruskal-Wallis test
Table S. Dynamic parameters of cancellous bone histomorphometry in 6 groups of uremic rats after administration of aluminum (A!) and
fluoride (F)
Nx Nx + Al Nx + F20 Nx + F40 Nx -I- Al + F20 Nx + Al + F40 P
MAR pin/day
AJ.AR pin/day
Md.BFR/RS
1,78 0.16
1.60 0.l4
0.36 0,O6
0.01 001b
<0.01"
<001"
1.00 o,15a.c
0.85 o.lla
0.19 0.04
1.20 0.09
1.01 0.l0a
0.22 0.02a
0.54 0.36b,c
0.02 0.02"
0.02 0.0!"
0.46 021b,6
0.01 0.01"
<0.01"
<0.001
<0.001
<0.001
pin3/pin2/day
Omt day 2.7 0.3 83.9 295b 6.6 0.9C 10.4 4.l 50.1 ÷ 261 87.3 28.1" <0.001
MIt day 3.0 0.4 — 7.6 0.9 13.5 5.8 — — NS
Values with the same superscript are not statistically different. Abbreviations are in the text. P denotes the result of the Kruskal-Wallis test (NS:
not significant).
When aluminum-treated rats were considered together, there
was a significant correlation between osteoid volume and
osteoblastic osteoid surface (r = 0.59, P <0.005). In contrast,
when data of group Nx + Al were excluded no such relationship
was found (r —0.16, P = 0.52). Furthermore, in this case
correlation analysis revealed an inverse relationship between
the number of osteoblasts per unit of osteoid perimeter length
and osteoid volume in fluoride-treated, aluminum-loaded rats
(r —0.65, P < 0.01).
Discussion
Early cases of adynamic bone disease in patients undergoing
hemodialysis have tentatively been related to the toxic effects
of fluoride [24]. However, subsequent investigations did not
substantiate this assumption [25, 26], and accumulation of
aluminum in bone has now been recognized as the etiological
factor involved in the pathogenesis of the majority of these
cases [27]. In the present study, a large parenteral aluminum
load resulted in a severe low turnover bone disease, as evi-
denced by an increase in osteoid volume and osteoid surface,
paucity of osteoblasts, and a marked fall in mineral apposition
rate and bone formation rate. In addition, bone aluminum was
clearly elevated and aluminum was demonstrable at the bone-
osteoid interface. These features have previously been de-
scribed in human and experimental aluminum-related bone
disease [8, 17, 27].
Aluminum treated rats had an accelerated progression of
renal disease resulting in marked secondary hyperparathyroid-
ism. Renal functional impairment has been observed previously
in experimental studies following large parenteral loads of
aluminum [28]. However, the mechanisms for this phenomenon
are subject to conjecture. Possible reasons include progressive
accumulation of aluminum in renal tissue and subsequent
tubular toxicity [29—311. In particular, mitochondrial damage
has been reported to occur in proximal tubular cells following
long-term administration of aluminum [32].
Cancellous bone of rats receiving sodium fluoride at two
different dose levels exhibited changes which were in part
opposite to and in part similar to the effects of aluminum. At the
cellular level the number of osteoblasts per unit osteoid peri-
meter length rose. However, evaluation of tetracycline labels
revealed a tendency for the mineral apposition rate to decrease
and for the osteoid maturation time to increase, suggesting that
a toxic effect on osteoblast function or on mineralization had
occurred. The effect was also apparent at the level of the basic
multicellular unit (BMU): Adjusted apposition rate tended to
decrease and mineralization lag time was prolonged. At the
tissue level mineralized bone formation rate tended to fall,
indicating that the inhibition of osteoblast function had out-
weighed the stimulatory effect on osteoblast proliferation.
The stimulatory actions of fluoride regarding alterations of
bone histology have been described earlier. Thus, at the tissue
level administration of fluoride has been found to augment
periosteal bone formation in cortical bone of the rat [33] and to
activate cancellous bone remodeling by stimulating the forma-
tion of new BMUs [34]. The increase in bone turnover is
thought to be a direct effect of fluoride on bone cell number and
activity [35] and may not require the development of secondary
hyperparathyroidism, which has been reported to occur in some
[33], but not all models of experimental fluorosis [36]. However,
prolonged administration of fluoride may exert considerable
toxic effects itself, and a narrow range between stimulatory and
depressive effects of fluoride in rats has been reported previ-
ously [37]. Like aluminum, fluoride will be deposited mainly in
a layer of mineral immediately adjacent to the trabecular
surface and at the mineralization front [381. Like aluminum,
fluoride may interfere with the mineralization process at the
cellular and at the I3MU level [33, 37,39]. Long-term effects of
Mineral apposition
rate (cell level)
Cell level
Fig. 2. Diagram to summarize some hypothetical interactions of aluminum (Al) and fluoride (F) based on the data of this investigation. Symbols
are: j stimulatory effect; ® inhibitory effect; (—) dose-dependent inhibitory effect which may not be present at lower dose levels or following other
modes of administration.
fluoride may include decreases in the life span and number of
bone cells rather than a persistent hypercellularity of bone
forming cells [34]. In support of these adverse findings at the
cellular level we observed a smaller increase in osteoblastic
osteoid by use of the larger fluoride dose and a fall in the
mineral apposition rate as compared to untreated uremic rats.
Mode of action as well as toxic events may be related to the
inhibitory or activating effects of fluoride on a variety of cellular
enzymes [40]. It is of particular interest that aluminum forms
strong complexes with fluoride which may participate in the
spectrum of effects previously ascribed to fluoride [41]. Since
both ions are mainly excreted by the kidney, an impairment of
excretory renal function should facilitate retention of fluoride
and aluminum and may thus aggravate mutual effects.
On the basis of these data it would appear difficult to predict
the interaction of fluoride and aluminum in bone of rats with
renal functional impairment. The results of our study confirm
that pretreatment and concurrent administration of fluoride
during parenteral aluminum loading does have a profound
impact on the evolution of aluminum-induced osteodystrophy
(Fig. 2). Stainable aluminum at the bone-osteoid interface rose
but the toxic suppression of the osteoblast number by aluminum
was fully antagonized by fluoride in a dose-dependent fashion.
By use of the smaller dosage of fluoride osteoblastic osteoid
surface was restored close to the level found in uremic rats
receiving fluoride alone. This finding is in sharp contrast to the
relative paucity of bone cells encountered in aluminum-intoxi-
cated bone [8, 9, 14]. Moreover, following combined adminis-
tration of high dose fluoride together with aluminum, the
number of osteoblasts surpassed the cell counts of the fluoride
groups and the extent of osteoblast surfaces was 6.4-fold larger
as compared to high dose fluoride alone. This finding provides
evidence of an unexpected interaction of fluoride and aluminum
resulting in complete reversal of aluminum-induced suppression
of osteoblasts and enhanced stimulatory activity of fluoride.
In rats loaded with aluminum and fluoride we observed an
accelerated accumulation of osteoid volume and a persistent
suppression of dynamic histomorphometric parameters both at
the cell and at the tissue level, suggesting an exacerbation of the
osteomalacic lesion. There was also a significant correlation
between the enlarged extent of osteoblastic osteoid surface and
the degree of osteoidosis. Furthermore, treatment with fluoride
resulted in a dose-dependent increase in stainable aluminum at
the bone-osteoid interface. Taken together, these data are
consistent with the view that in the presence of fluoride the
aluminum-induced bone lesion is the consequence of either
direct physico-chemical interference with the mineralization
process or osteoblast dysfunction rather than depression of
osteoblast number.
Our findings are at variance with previous observations of
Sedman et al, who reported an aluminum-induced fall in bone
formation primarily due to a decrement of active osteoblasts
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[14]. This discrepancy may be attributed to the following
considerations: Bone aluminum content in the present study
was considerably higher than in the aforementioned investiga-
tion. Thus, direct interference of aluminum with the mineral-
ization of osteoid may represent a dose-related phenomenon
taking place at a higher aluminum concentration in bone.
Consistent with this view aluminum-induced inhibition of apa-
tite formation and growth in vitro has been reported to occur in
a dose-dependent manner [5]. In an animal model of acute
aluminum overload evidence has been generated for the rele-
vance of both mechanisms of aluminum toxicity, depression of
osteoblast surface as well as direct inhibition of mineralization
[42]. It is possible that deposition of aluminum-fluoride com-
plexes at the mineralized bone-osteoid interface disturb miner-
alization more effectively than aluminum itself. Fluoride per se
has been found to delay the onset of mineralization [33, 39], and
a prolonged mineralization lag time in uremic rats treated with
fluoride alone was encountered in this investigation. It is
equally possible that aluminum together with fluoride could
have impaired osteoblastic functions, thereby increasing osteo-
blast number but reducing osteoblast ability to promote miner-
alization of bone matrix. Despite these uncertainties, adminis-
tration of fluoride concomitant with exposure to aluminum
creates a particular situation where fluoride antagonizes the
osteoblast-depressive effect of aluminum but exacerbates the
osteomalacic state.
By analogy, exogenous PTH in short-term experiments has
been demonstrated to overcome an aluminum-induced suppres-
sion of osteoblasts without improvement of bone mineralization
[42]. Both exogenous and endogenous PTH worsened osteo-
idosis [42, 43]. In the present study an appreciable degree of
secondary hyperparathyroidism failed to counteract the de-
crease of osteoblastic osteoid surface following a larger alumi-
num load over a more extended period of time. Even under
these circumstances fluoride proved to be a powerful stimulator
of osteoblast cell number. There was a dose-related rise in
Ob.SIBS, Ob.S/OS and N.Ob/O.Pm. On the other hand, pooled
data of fluoride-treated, aluminum-loaded rats revealed a neg-
ative correlation between osteoblast number and osteoid vol-
ume. In the presence of an almost complete inhibition of
mineralization this finding may point to a fluoride-induced toxic
impairment of osteoblast ability to synthesize bone matrix. This
adverse action occurred in addition to the mineralization defect
induced by fluoride, which was obvious in rats not exposed to
aluminum, indicating that fluoride is not a benign substitute for
PTH to stimulate the number of bone forming cells.
Both vitamin D status and PTH have been reported to
modulate the accretion rate of aluminum in bone [17, 43, 441.
Apparently, a similar effect may also be ascribed to fluoride.
Addition of fluoride to the drinking water resulted in a signifi-
cant decrement in bone aluminum content as compared to
aluminum loading without fluoride. In addition, fluoride
changed the pattern of aluminum deposition in cancellous bone.
Thus, we observed an increase in stainable aluminum at bone-
osteoid interfaces and a decline of aluminum-positive mineral-
ized surfaces. These latter phenomena appeared to be dose-
related. The reasons for the aberrant compartmentalization of
aluminum in cancellous bone are not readily apparent, how-
ever, several possible mechanisms have to be considered. The
decrease in bone aluminum deposition was not attributable to
better preservation of glomerular filtration in fluoride-exposed
rats. Renal function deteriorated to a similar degree in alumi-
num-loaded rats regardless of fluoride treatment, and urinary
excretion rates of aluminum were also comparable among
aluminum-injected groups. Likewise, the degree of secondary
hyperparathyroidism was similar among aluminum-loaded rats,
and experimental fluorosis has also been shown not to affect
renal synthesis of calcitriol [36, 37]. This suggests that changes
in the serum concentrations of calcium regulating hormones did
not account for differences in aluminum deposition.
It is of note that fluoride did not affect the deposition of
aluminum in spleen or liver, in both of which fluoride does not
accumulate to an appreciable degree. Our data do not support
suggestions that fluoride may promote aluminum deposition in
liver and spleen, and they do not corroborate previous findings
of a positive correlation between bone content of fluoride and
aluminum [45, 46]. However, the present data are consistent
with the view that the modulation of aluminum accumulation in
bone was mediated by fluoride directly rather than by indirect
mechanisms. Fluoride might have affected bone aluminum
content by a change in the turnover rate of skeletal sites
accessible to aluminum [47]. Yet no significant increases in
bone formation rates were discernible subsequent to fluoride
ingestion. Fluoride is readily adsorbed to hydroxyapatite at the
mineralization front and finally becomes incorporated into bone
mineral to form fluoroapatite [48, 49]. Since fluoride has also a
high affinity to aluminum [41] it is conceivable that aluminum
deposition was facilitated at the bone-osteoid interface, where
fluoride concentration would be expected to be high. Thus,
formation of aluminum-fluoride complexes at the mineralization
front may have trapped aluminum at this site and may have
prevented a more diffuse pattern of aluminum deposition in
mineralized bone or at neutral bone surfaces. In addition, it is
possible that fluoride-induced changes in collagenous matrix or
packing density of mineral crystals contributed to the altered
pattern of aluminum accumulation in bone.
We cannot exclude that the larger number of osteoblasts in
fluoride exposed rats moved greater amounts of aluminum to
the bone-osteoid interface. However, up to now it has not been
demonstrated that deposition of aluminum at the bone-osteoid
interface depends on the number of osteoblasts lining the
osteoid surface rather than on the extension of the bone-osteoid
interface. Likewise, we cannot exclude that the larger number
of osteoblasts in fluoride treated rats may have removed alumi-
num from bone. However, it is equally possible that these bone
resorbing cells were removing bone formed prior to aluminum
exposure containing less aluminum, and that any aluminum
released would be redistributed within bone in the presence of
markedly elevated serum aluminum concentrations.
In conclusion, the present data suggest that administration of
fluoride fully antagonizes the aluminum-induced suppression of
osteoblast number, but does not improve mineralization,
thereby resulting in an exacerbation of the osteomalacic lesion
of aluminum-related bone disease. Furthermore, fluoride has a
distinct effect on the pattern of aluminum deposition in bone.
Thus, exposure to fluoride will have to be considered when
evaluating aluminum-related bone disease in clinical cases or in
experimental models.
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